Other News

SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments

Members of the SHERPA project team

Members of the SHERPA project team

Philips Azurion interventional oncology procedure

Philips Azurion interventional oncology procedure

SHERPA project logo

SHERPA project logo

March 3, 2026 With a total budget of EUR 21.5 million, the four-year SHERPA research project is coordinated by Philips and co-funded by the EU Innovative Health Initiative (IHI) and industry partnersThe project focuses on developing automated workflows for minimally invasive neurovascular and tumor treatments – clinical procedures where staffing levels and specialized expertise are in short supplyThe clinical studies are being conducted at University Medical Center Utrecht, St Antonius Hospital, University Medical Center Hamburg-Eppendorf, Hôpital Bicêtre AP-HP, and Hospital de la Santa Creu i Sant PauOn March 4 (16:30 – 17:30 CET), SHERPA will be featured at the European Congress of Radiology 2026 in a dedicated session Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the Philips-coordinated SHERPA research consortium has initiated seven clinical studies to demonstrate the benefits of AI- and robotics-assisted workflows in minimally invasive treatments for brain aneurysms* and liver tumors. Staff shortages, coupled with the complex nature of the work, place significant pressure on interventional radiologists and interventional neuroradiologists who perform these procedures. The SHERPA consortium aims to validate AI-powered technologies in imaging, data visualization, procedure planning and guidance, clinical decision support, and patient pathway orchestration. These technologies are designed to automate repetitive, time-consuming tasks, support decision-making, and accelerate learning to ease the workload of interventional (neuro)radiologists. The four-year research project is co-funded by the industry partners through in-kind contributions and additional resources, as well as by the European Union Innovative Health Initiative (IHI), and comprises 16 partners from seven European countries. “Over the past year, the SHERPA project has brought together a talented team of researchers who have developed a technology framework designed to make workflow automation a reliable companion – a ‘sherpa’ – for interventional (neuro)radiologists as they navigate some of their most complex procedures,” said Bert van Meurs, Chief Business Leader, Image Guided Therapy, at Royal Philips. “By providing a template for the future adoption of AI-enabled assistive technologies and accelerating the associated learning curve, this framework will help address the increased demand for interventional (neuro)radiologists in Europe and beyond.” “Demand for image-guided, minimally invasive procedures has outpaced the growth of the specialized workforce,” said Irene van der Schaaf, Professor Neurovascular Interventional Radiology, UMC Utrecht. “At the same time, procedures are becoming more complex and technology is advancing rapidly, making it harder for teams to keep pace. In interventional radiology, technology and human touch go hand in hand. Physicians must manage highly technical tasks – sometimes away from the patient – while continuing to provide personal care and reassurance. The SHERPA project aims to develop AI-enabled tools that simplify routine tasks, enhance patient care, and support the training of the next generation of interventional (neuro)radiologists.” On March 4, 2026, from 16:30 to 17:30 CET, SHERPA will be featured at the European Congress of Radiology (ECR) 2026 in a dedicated session titled: “Assistive Technologies for Interventional Radiologists: Enhancing Decision-Making and Streamlining Workflow with Innovations and AI-Powered Solutions.” Click here to view the agenda and register to attend the session online. Innovation through public-private partnershipThe SHERPA public-private partnership consortium comprises five medical technology industry partners, five academic partners, and five research organization and medical association partners: Industry partners: Philips, Medtronic, Sim&Cure, Interventional Systems, Barco.Academic partners: University Medical Center Utrecht (The Netherlands), University Medical Center Hamburg-Eppendorf (Germany), Hôpital Bicêtre AP-HP (France), Hospital de la Santa Creu i Sant Pau (Spain), St Antonius Hospital (The Netherlands).Research organization and medical association partners: European Institute for Biomedical Imaging Research – EIBIR, Cardiovascular and Interventional Radiological Society of Europe – CIRSE, European Society of Minimally Invasive Neurological Therapy – ESMINT, Eindhoven University of Technology – TU/e (The Netherlands), Human-Factors-Consult – HFC (Germany). Addressing staff shortages and patient access by relieving the pressure on physiciansThe World Health Organization (WHO) predicts a shortage of 600 thousand physicians in the European Union (EU) by 2030 [1]. Some of the most acute physician shortages are in interventional radiology, even in countries such as the UK that have advanced healthcare systems [2]. Among the many different procedures conducted by interventional (neuro)radiologists, treatments of brain aneurysms and liver tumors are some of the most complex and time consuming. Both rely on CT and/or MR imaging for diagnosis, real-time imaging for procedure guidance, and a high level of precision in the placement of therapeutic devices such as blood-clot inducing platinum coils to seal off a brain aneurysm or the percutaneous insertion of ablation needles to treat a liver tumor. As a result, these procedures require a very high level of operator expertise and training, which can limit patient access. The SHERPA project aims to provide interventionists with AI-powered assistive technologies that automate repetitive tasks and support decision-making across the entire workflow. By doing so, they will accelerate learning curves and improve precision and safety in complex minimally invasive interventions such as brain aneurysm repair and liver tumor ablation. During the first year of the project, the consortium successfully developed AI algorithms to help identify brain aneurysms that need treatment and algorithms to optimize patient selection and therapy planning for liver tumor ablation. They also developed robotic technology to improve procedure precision and reduce difficulty, and AI software to confirm treatment success. These have now been integrated into orchestrated end-to-end workflows for both types of procedure. SHERPA project clinical studiesOver the next three years of the four-year SHERPA project, the consortium partners will conduct a series of clinical studies to refine these assistive technologies and assess the benefits in terms of the patient experience, workload optimization, interventionist satisfaction, and performance. The five brain aneurysm studies will focus on AI-driven aneurysm detection, risk prediction, and precise treatment planning: RADAR: AI-based aneurysm detection based on CT and MR imaging.Aneurysm@risk: AI-based algorithm to predict aneurysm growth and rupture risk.ASSIST: AI-supported device selection and positioning guidance.INTERACT: Automatic collimation and projection angle suggestions to optimize imaging for procedural guidance.SAFO: Evaluation of a digital remote follow-up solution for brain aneurysm patients, enabling standardized monitoring, enhanced coordination, and seamless care across the patient pathway. The liver and lung tumor studies will leverage advanced imaging and robotic-assisted biopsy technologies, respectively, to drive greater diagnostic precision and procedural efficiency. MISTRAL: Evaluation of new Cone Beam CT workflows to optimize imaging for percutaneous liver ablations.RHODES: Evaluation of robotic-assisted versus free-hand lung biopsies with a focus on operability and device efficiency. Together, these studies will generate insights to support the acceptance and adoption of AI-based smart assistive technologies by the wider interventional radiology community. The SHERPA website can be viewed at: https://sherpa-ihi.eu. Watch videos and interviews about SHERPA here. The CORDIS project page for SHERPA can be accessed here, and the IHI factsheet for SHERPA can be found here. Notes and references*        A brain aneurysm is a weak, bulging spot in a blood vessel in the brain, which can leak or rupture.[1]     Zapata T, Muscat NA, Falkenbach M, and Wismar M. WHO Report – From Great Attrition to Great Attraction: Countering the Great Resignation of Health and Care Workers. Eurohealth, Vol.29, No.1, 2023. https://iris.who.int/server/api/core/bitstreams/488b01ab-a066-4558-a345-476570fe2802/content[2]     The Royal College of Radiologists: Clinical radiology – UK workforce census 2020 report. https://www.rcr.ac.uk/media/3gjdr23o/clinical_radiology_census_report_2020.pdf This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194744. The JU receives support from the European Union’s Horizon Europe research and innovation program and life science industries represented by COCIR, EFPIA, Europa Bío, MedTech Europe and Vaccines Europe. SHERPA is Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or Innovative Health Initiative Joint Undertaking. Neither the European Union nor the granting authority can be held responsible for them. Media ContactSteve KlinkPhilips Medical and Scientific CommunicationsTel: +31 6 10888824E-mail: steve.klink@philips.com Joost MalthaPhilips Global External RelationsTel: +31 6 10558116E-mail: joost.maltha@philips.com About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments

Members of the SHERPA project team

Philips Azurion interventional oncology procedure

SHERPA project logo

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts. The presentations include late-breaking clinical data, oral sessions and posters highlighting real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements and changes in advanced hemodynamic, respectively.  Late-Breaking REBALANCE Registry Data In a late-breaking presentation on Monday, March 2, Dr. Dmitry Yaranov will share, for the first time, data from the REBALANCE Registry, a post-market observational study designed to evaluate real-world data on the safety and benefit of Barostim therapy in the commercial setting. Dr. Yaranov will present the six-month outcomes in over 400 patients enrolled in the registry. Scientific Presentations Featuring Barostim Monday, March 2: Late-Breaking Clinical Science Session 1: Initial Six-Month Outcomes with Baroreflex Activation Therapy from the REBALANCE Registry (Dr. Dmitry Yaranov)Unmasking the Energetic Response Following Acute Titration of Baroreflex Activation Therapy Through Patient-Specific Modeling and Simulation (Dr. Rohan Goswami)Impact of Baroreflex Activation Therapy on Hospitalizations: A Single Center Retrospective Analysis (Dr. Joel Joseph) Tuesday, March 3: Electrical Therapies for Heart Failure: Barostimulation for HFrEF (Dr. Philip Adamson)Abstract Session 8: Heart Failure Reduced Ejection Fraction I Real-World Outcomes of Barostim Baroreflex Activation Therapy in Heart Failure: Analysis of a Large Multi-Institutional Database (Dr. Arvind Bhimaraj)LVEF and Functional Improvement Observed in a Post-Market Registry of Barostim Baroreflex Activation Therapy (Dr. Dmitry Yaranov) CVRx Sponsored Satellite Program CVRx will also host a satellite program on Tuesday, March 3 from 12:15-1:30 p.m. ET in Ensemble CD South, which will include the following presentations: Advances in Evidence with Baroreflex Activation Therapy (Dr. Philip Adamson)Outcomes from the REBALANCE Registry (Dr. Dmitry Yaranov)BREATHE-HF: Impact of Barostim Therapy on Cardiac Hemodynamics (Dr. Gabriel T. Sayer)BENEFIT-HF: Broadening Access to Barostim Therapy (Dr. Farooq Sheikh) During the satellite program, faculty will provide updates on the REBALANCE Registry, the BREATHE-HF trial, and the BENEFIT-HF trial. BREATHE-HF, a large physician-initiated study, is evaluating the impact of Barostim on cardiac hemodynamics. In January, CVRx announced the initiation of the BENEFIT-HF trial, a landmark randomized study supported by CMS Category B IDE coverage. The trial is designed to evaluate the impact of Barostim in a significantly expanded heart failure population, with the primary endpoint as a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026. “We are excited by the new data supporting Barostim being featured at THT 2026,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are encouraged by the increasing adoption of Barostim by the heart failure community. The accelerating cadence of publications evaluating Barostim’s impact is proof of the positive patient impact and increasing acceptance of Barostim in the heart failure treatment continuum.” About CVRx, Inc.CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding the expected enrollment of the BENEFIT-HF clinical trial and anticipated benefits of Barostim therapy. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our expectations regarding enrollment, the resulting impact of our addressable market and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.comMedia Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com

Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference

New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). “We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate nex-z in a broad ATTR-CM population,” said Intellia President and Chief Executive Officer John Leonard, M.D. “With the resolution in January of the clinical hold on our MAGNITUDE-2 Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials. We appreciate the FDA’s responsiveness throughout this process and thank the many investigators and patients who are participating in these trials.” The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed by the FDA on October 29, 2025, following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in MAGNITUDE that met the trial’s protocol-defined pausing criteria. The company has aligned with the FDA on mitigation measures for MAGNITUDE and MAGNITUDE-2 that include enhanced monitoring of liver laboratory tests, guidance for short-term steroid treatment if elevated liver transaminases are observed in the initial period following dosing and the exclusion of patients with certain liver abnormalities. For MAGNITUDE, additional exclusion criteria are being incorporated for patients with a recent history of cardiovascular instability and those with ejection fraction

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted of 1,840,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase 240,000 additional shares, at a price to the public of $125.00 per share. The aggregate gross proceeds to Palvella from this offering, before deducting underwriting discounts and commissions and offering expenses, were $230.0 million.

Neuro Tech Forum 2026

By partnering with the Neuro Tech Forum, CardiacVascular News gives its audience a front row seat to where neuro innovation is headed. The event convenes founders, researchers, clinicians, and investors who are actively building and backing the next wave of neurotechnology. It is a strong editorial fit for CardiacVascular News’ […]

Herz P1 Smart Band 2026: What It Tracks, How It Works, and What Consumers Should Know Before Buying

A 2026 Informational Overview of the Herz P1 Smart Band’s Subscription-Free Health Monitoring Features, Heart Rate and HRV Tracking, Sleep Quality Analysis, Blood Oxygen and SpO2 Sensors, Stress and Temperature Monitoring, 30-Day Battery Life Claims, Companion App Functionality, Pricing Structure, Return Policy Terms, Sensor Technology Explained, Water Resistance Specifications, and What Consumers Should Independently Verify Before Purchasing Any Fitness Tracker or Wearable Health DeviceAkron, OH, Feb. 26, 2026 (GLOBE NEWSWIRE) — This article is for informational purposes only. The Herz P1 Smart Band is a consumer wellness product and is not a medical device. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Consumers should consult a qualified healthcare professional before making health decisions based on data from any wearable device. This article contains affiliate links. If you click through and make a purchase, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented. The consumer wearable market continues to expand in 2026, with fitness trackers, smart bands, and health monitoring devices competing for attention across a crowded category. For consumers researching their options, sorting through feature claims, pricing models, and subscription structures can feel overwhelming. The Herz P1 Smart Band is one product that’s entered this space, marketed as a subscription-free wrist-worn health tracker with a long battery life and multi-metric monitoring capabilities. This informational overview examines what the Herz P1 Smart Band offers, how its features are described by the company, what the pricing structure looks like, and what consumers should independently verify before purchasing any fitness wearable in this category. The wearable technology space moves quickly, and product specifications, pricing, and availability can change without notice. Any product details are described as stated by the company and should be verified on the official site and directly with the manufacturer. The Herz P1 Smart Band is a consumer wellness product, not an FDA-cleared or FDA-approved medical device, and health monitoring results are not guaranteed. The information below is compiled from publicly available materials and does not represent clinical evaluation, independent laboratory testing, or editorial endorsement of the product or company. To view the current Herz P1 Smart Band offer (official Herz P1 page), consumers can check the complete product details, pricing, and return policy directly. What the Herz P1 Smart Band Is The Herz P1 Smart Band is a wrist-worn consumer wellness and fitness tracker manufactured by WuzuTech LLC, a company based in Akron, Ohio. The company positions the device as a general wellness tool designed for continuous 24/7 health monitoring. It is not classified as a medical device, and the company’s own health disclaimer states that the product and related services “are for general wellness and fitness purposes only and are not intended to be used as a medical device or to replace professional medical advice, diagnosis, or treatment.” The company states that the Herz P1 Smart Band tracks over 20 health and activity metrics using optical heart rate sensors, motion sensors, and temperature sensors built into the device. Data from the band syncs to the Herz companion app, which is available on both iOS and Android. Per the company’s published materials, the device is a one-time purchase with no recurring subscription fees required to access health data or app features. Wearable products in this category use different pricing and app-access models — some include subscription-based features, while others are offered as one-time purchases. Consumers can verify current access terms on the official product page. Regulatory Classification and General Wellness Wearables In the United States, some consumer wearables are marketed as “general wellness” products. The FDA has published guidance describing its enforcement policy for low-risk general wellness products and how they differ from devices intended for diagnosis or treatment. These products may provide estimates and trend insights related to activity and wellness but aren’t intended to diagnose, treat, cure, or prevent disease. The company markets the Herz P1 Smart Band for general wellness and fitness purposes, and states it is not intended to be used as a medical device or to replace professional medical advice. This means the data it provides — heart rate estimates, sleep pattern approximations, SpO2 readings, and activity metrics — should be understood as trend indicators, not clinical measurements. Consumers should avoid using wearable readings as a substitute for clinical evaluation, especially for medical decisions involving heart conditions, oxygenation concerns, unusual temperature patterns, or sleep disorders. Anyone with specific health concerns should consult a licensed healthcare provider who can recommend appropriate monitoring tools. How the Herz P1 Smart Band Works The company’s materials describe the device as using a combination of sensor technologies to collect biometric and activity data from the wearer’s wrist throughout the day and night. The collected data is transmitted via Bluetooth to the Herz companion app (also referenced as QRing), where it’s organized into reports and insights. Optical Heart Rate Sensors — the company states these continuously monitor heart rate and heart rate variability (HRV), providing data on cardiovascular patterns during both active and resting periods. Motion Sensors — accelerometer technology is described as tracking steps, distance, calories burned, and activity intensity throughout the day. Temperature Sensors — the company’s documentation references continuous skin temperature monitoring, which is described as helping users identify patterns related to recovery and overexertion. Blood Oxygen (SpO2) Monitoring — the device is described as measuring blood oxygen saturation levels, which the company frames as relevant to understanding energy levels and respiratory patterns. Per the company’s website, the band also includes stress tracking capabilities and sleep analysis features that monitor sleep stages and quality metrics overnight. What the Herz P1 Smart Band Tracks Based on publicly available information from the company, the Herz P1 Smart Band is described as monitoring the following categories of health and activity data: Heart Rate and HRV — continuous heart rate monitoring and heart rate variability tracking, which the company describes as useful for understanding recovery and cardiovascular health patterns over time. Sleep Quality and Analysis — the company states the band monitors sleep patterns overnight and provides sleep quality insights through the companion app. Blood Oxygen (SpO2) — the device is described as tracking blood oxygen saturation, with data accessible through the app. Skin Temperature — continuous temperature monitoring is referenced in the company’s feature descriptions. Stress Tracking — the company’s materials describe real-time stress monitoring that shows when the body is under strain and how it recovers. Activity Metrics — steps, distance, and calories burned are described as core tracking features. Women’s Health Insights — the company references menstrual cycle tracking capabilities that provide insights into how the cycle affects energy, sleep, and mood. All tracking capabilities described above come from the manufacturer’s publicly available materials. Wrist-worn consumer wellness devices use sensor technologies that provide estimates and trend data — not clinical measurements. Accuracy can vary based on device fit, skin type, motion, environmental conditions, and individual physiology. Consumers who need medically reliable biometric data should consult with a healthcare provider about appropriate monitoring tools. Pricing and Purchase Structure The Herz P1 Smart Band is sold as a one-time purchase through the company’s official website. Wearable products in this category use different pricing models — some require recurring subscriptions to unlock full feature access, while others include all features with a one-time purchase. The company states the Herz P1 Smart Band doesn’t require a recurring subscription to access its companion app features. According to publicly available information on the official website at the time of publication, pricing may vary based on promotions, bundles, and inventory conditions. Consumers should check the official Herz P1 page to confirm the most current pricing, shipping costs, and policy terms before making any purchase decision. The company’s materials state that the purchase includes the smart band, charging cable, and straps. Additional color bands may be sold separately. The company references a 90-day return policy on its official page. Consumers should verify eligibility requirements, timelines, and return shipping responsibilities directly in the published policy before purchasing. Battery Life, Build Quality, and Design The company states the Herz P1 Smart Band contains a 175 mAh battery and describes the following performance characteristics: Active Use Battery Life — the company states up to 25–30 days of regular use on a single charge. Standby Battery Life — up to 60 days of standby time is referenced in the company’s materials. Charging Time — the company states the device fully recharges in approximately 1 to 1.5 hours. Regarding build quality, the company’s documentation describes the device as constructed from a lightweight zinc alloy frame with a durable nylon strap. The company states the band is water-resistant and sweat-proof, suitable for workouts and daily wear. The company’s official product page references water resistance but advises against swimming or full submersion. The Herz P1 Smart Band is described as available in five color options: Midnight Black, Frosted White, Green Power, Navy Blue, and Rose Mist. Battery life and water resistance claims come from the manufacturer. Actual performance may vary based on notification settings, sensor sampling frequency, Bluetooth connectivity, display behavior, device fit, and environmental conditions. Consumers should check the complete product specifications on the official site before purchasing. Companion App and Data Access The company states that the Herz P1 Smart Band syncs with a companion app available for both iOS and Android. The app is described as providing detailed health and fitness reports, goal-setting features, and progress tracking over time. Per the company’s materials, the app supports over 30 languages. The band also includes offline data storage. The company states that if Bluetooth is disconnected, the device can store health data locally for several days. Once reconnected, stored data syncs automatically with the companion app. Consumers should verify app compatibility with their specific device and operating system version before purchasing. What Consumers Commonly Verify Before Purchasing Based on common consumer research patterns in the wearable technology category, here are areas that prospective buyers typically investigate before purchasing a fitness tracker: Accuracy Expectations: Consumer wellness wearables vary in accuracy across different metrics. No wrist-worn consumer device provides clinical-level precision. The company states its device tracks various metrics, but consumers seeking medically reliable data should consult a healthcare provider. Return Policy Terms: The company references a 90-day return policy on its official page. Consumers should verify the specific terms, conditions, and process for returns directly on the company’s website before purchasing. Company Background: WuzuTech LLC is listed as the manufacturer, based in Akron, Ohio. Consumers can verify the company’s business registration, customer service responsiveness, and fulfillment track record independently. App Functionality: Checking the companion app’s current version, update frequency, and user feedback in the iOS App Store or Google Play Store before purchasing can provide additional perspective on the overall experience. Comparison Shopping: Consumers often compare wearables based on sensor types, sampling frequency, battery life under real-world settings, return policy clarity, app permissions, and whether full feature access requires ongoing fees. Evaluating multiple products across these criteria helps inform a purchasing decision. Water Resistance vs. Waterproofing: The company describes the device as water-resistant and suitable for sweat and splashes but advises against swimming or full submersion. Consumers should understand the difference between water resistance ratings before wearing any device in water. Key Terminology for the Consumer Wearable Category Heart Rate Variability (HRV): HRV measures the time variation between heartbeats. In consumer wellness contexts, it’s commonly used as an indicator of recovery and stress. HRV readings from consumer wearables are estimates and shouldn’t be used for medical diagnosis. Blood Oxygen Saturation (SpO2): SpO2 refers to the percentage of oxygen-carrying hemoglobin in the blood. Consumer wearable SpO2 readings are approximations and aren’t equivalent to pulse oximeter readings obtained in clinical settings. Photoplethysmography (PPG): PPG is the optical sensor technology commonly used in consumer wearables to detect blood volume changes beneath the skin. It’s the foundational technology behind heart rate and SpO2 monitoring in most fitness trackers and smart bands. General Wellness Device: A category described in FDA guidance for products intended to promote a healthy lifestyle. General wellness devices aren’t intended to diagnose, treat, cure, or prevent disease and don’t follow the same regulatory pathway as medical devices. Subscription-Free Model: In the wearable category, some manufacturers require monthly or annual subscriptions to access full data insights and features. Subscription-free models provide full feature access with a one-time purchase. Fitness Tracker vs. Smartwatch: A fitness tracker or smart band typically focuses on health and activity monitoring with a lighter design and longer battery life. Smartwatches generally offer broader app functionality, larger displays, and shorter battery life. The Herz P1 Smart Band falls into the fitness tracker and smart band category. Consumer Questions About the Herz P1 Smart Band Is the Herz P1 Smart Band a medical device? No. The company explicitly states that the Herz P1 Smart Band is a general wellness and fitness product. It isn’t intended to diagnose, treat, cure, or prevent any disease or medical condition. The company’s health disclaimer directs consumers to consult a qualified healthcare professional for medical advice. Who manufactures the Herz P1 Smart Band? The Herz P1 Smart Band is manufactured by WuzuTech LLC, a company based in Akron, Ohio. Consumers can verify the company’s business details and contact information independently. Does the Herz P1 Smart Band require a monthly subscription? The company states that no subscription is required. All health data and app features are described as accessible with the one-time device purchase. Consumers should verify this on the official website, as company policies can change. What phone compatibility does the Herz P1 Smart Band support? The company states the device works with both iOS and Android devices through a free companion app. Consumers should verify specific operating system version requirements before purchasing. How long does the Herz P1 Smart Band battery last? The company states up to 25–30 days of regular use on a single charge, with up to 60 days of standby time. Actual battery performance may vary based on usage patterns and settings. The company states charging takes approximately 1 to 1.5 hours. Is the Herz P1 Smart Band waterproof? The company describes the device as water-resistant and suitable for sweat, rain, and hand-washing. However, the company advises against swimming or fully submerging the device. Consumers should check the specific water resistance rating on the official product page. What metrics does the Herz P1 Smart Band track? The company states the device tracks over 20 health and activity metrics, including heart rate, HRV, SpO2, temperature, sleep quality, stress levels, steps, distance, and calories burned. All accuracy claims come from the manufacturer. Does the Herz P1 Smart Band store data offline? The company states the device can store health data locally for several days if Bluetooth is disconnected. Stored data syncs automatically once Bluetooth is reconnected. What is the return policy for the Herz P1 Smart Band? The company references a 90-day return policy on its official page. Consumers should verify eligibility requirements, timelines, and return shipping responsibilities directly in the published policy before purchasing. How does the Herz P1 Smart Band compare to smartwatches? Smart bands and smartwatches serve different purposes. Smart bands like the Herz P1 generally focus on health and fitness tracking with lighter designs and longer battery life. Smartwatches typically offer broader app ecosystems, larger displays, notification management, and shorter battery life. The right choice depends on individual priorities and what you’re looking for in a wearable. Where can consumers purchase the Herz P1 Smart Band? The company’s official website is the primary direct purchase channel. The product has also been listed on third-party retail platforms. Consumers should verify they’re purchasing from an authorized source. What colors are available for the Herz P1 Smart Band? The company’s materials reference five color options: Midnight Black, Frosted White, Green Power, Navy Blue, and Rose Mist. Availability may vary. Additional Category Context Consumers researching subscription-free fitness trackers often evaluate several areas beyond any single product’s feature list. Understanding how optical wrist sensors estimate heart rate and SpO2, what app privacy and data permissions look like, how battery life performs under real-world conditions, and what return and warranty terms actually require are all part of informed decision-making in this category. This article focuses on those evaluation areas using publicly available product disclosures from the Herz P1 Smart Band manufacturer. Consumers are encouraged to apply the same research approach across any wearable they’re considering. For additional context on the broader Herz P1 product line, a separate informational overview examines the company’s smart ring offering — including its features, pricing, accuracy context, and what consumers should verify before purchasing. Read the full informational analysis here. A separate informational overview also examines the company’s smart scale product, including its 8-electrode BIA sensor technology, body composition metrics, and what consumers should verify about accuracy claims for any home health measurement device. Read the full informational overview here. Both analyses were published for informational purposes and are not endorsements or recommendations. A Consumer Verification Checklist for Any Health-Tracking Wearable Before purchasing any health-tracking wearable — including the Herz P1 Smart Band — consumers can strengthen their decision-making by independently verifying the following areas. This checklist isn’t specific to any single product. It’s a framework that applies across the entire consumer wearable category. Verify the App Name and Developer: Download and check out the companion app before purchasing the hardware. Look at who developed it, when it was last updated, and what the current user feedback looks like. The Herz P1 Smart Band syncs with an app referenced as the Herz app or QRing, available on iOS and Android. Check App Permissions: Before installing any health-tracking app, look at what data permissions it requests. Common requests include Bluetooth, location, health data access, and notification permissions. Understand what data the app collects and how it’s stored or shared. Confirm Data Export Options: Some consumers want to export their health data to share with healthcare providers or use with other platforms. Check whether the companion app allows data export and in what formats before committing to a device ecosystem. Read the Return Policy in Full: Don’t rely on summary language. Read the actual return policy terms, including who pays return shipping, whether the device must be in original packaging, and how refunds are processed. The company states a return policy is available on the official Herz P1 website. Check Warranty Terms: Look at what the warranty covers, how long it lasts, and what the claims process involves. Manufacturer warranties for consumer electronics vary significantly in scope and responsiveness. Understand Sensor Limitations: Consumer wearables use optical sensors (PPG), accelerometers, and temperature sensors that provide estimates — not clinical measurements. Factors like skin tone, tattoos, wrist fit, motion, and environmental temperature can affect reading accuracy across all consumer wearable brands. Clarify Water Resistance vs. Waterproofing: These terms mean different things. Check the specific rating. The Herz P1 Smart Band is described as water-resistant and suitable for sweat and splashes, but the company advises against swimming or full submersion. Test Customer Support Responsiveness: Before purchasing, consider sending a pre-sale question to the company’s support team. Response time and quality can give you a sense of what post-purchase support looks like. Ask About Firmware Updates: Wearable devices often receive firmware updates that can affect performance, features, and battery life. Check whether the manufacturer has a track record of providing updates and how they’re delivered. Confirm Device Compatibility: Verify that your specific phone model and operating system version are compatible with the companion app before purchasing. Compatibility requirements can change with operating system updates. Summary of Key Considerations The Herz P1 Smart Band enters 2026 as a subscription-free consumer wellness wearable in a crowded fitness tracker category. The company’s advertised feature set — including 20+ health metrics, up to 30-day battery life, and no recurring fees — positions it as one option among many for consumers exploring accessible health monitoring. As with any consumer wellness device, prospective buyers should understand that the Herz P1 Smart Band is not a medical device and shouldn’t be used as a substitute for professional medical advice, diagnosis, or treatment. All feature claims, accuracy statements, and performance specifications referenced in this article come from the manufacturer’s publicly available materials and haven’t been independently verified through clinical testing as part of this overview. Consumers interested in the complete product details, current pricing, and return policy can view the current Herz P1 Smart Band offer (official Herz P1 page) directly. Contact Information WuzuTech LLC 839 E Market St, Ste 106 #165 Akron, OH 44305 United States Email: support@wuzutech.com Phone: (866) 479-1629 Website: https://herzp1.com Disclaimers Content and General Wellness Disclaimer: This article is for informational purposes only and does not constitute medical advice, professional health guidance, or a product endorsement. The Herz P1 Smart Band is a consumer wellness product, not a medical device. Statements regarding the product have not been evaluated by the Food and Drug Administration. The device is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Consumers should consult with a qualified healthcare professional before making health-related decisions based on data from any consumer wearable device. All product descriptions, features, and specifications referenced in this article are based on the manufacturer’s publicly available materials and have not been independently verified through clinical testing. Results, Pricing, and Availability Notice: Individual results and experiences with consumer wellness wearables vary based on usage patterns, device fit, individual physiology, environmental conditions, and other factors. No specific outcomes are guaranteed. Pricing referenced in this article reflects publicly available information at the time of publication and is subject to change without notice. Consumers should verify all current pricing, shipping costs, and return policy terms directly on the company’s official website before purchasing. FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If you click through these links and make a purchase, a commission may be earned at no additional cost to you. This affiliate relationship does not influence the informational content, accuracy, or editorial independence of this article. The publisher is not responsible for the accuracy of information provided by the manufacturer, changes to the product or its availability, or the consumer’s individual experience with the product or company. Consumers are encouraged to conduct their own research and due diligence before making any purchase decision. CONTACT: Email: support@wuzutech.com
Phone: (866) 479-1629